Business Context and Reporting Period
This Form 8-K Current Report was filed by Healthcare Realty Trust Incorporated on January 7, 2026, reporting events occurring on January 5, 2026. The filing addresses significant changes in executive leadership, specifically the departure of the Chief Financial Officer and the appointment of a successor.
Key Financial Metrics and Compensation
The filing does not report operational financial metrics such as revenue, profit, cash flow, or debt levels. Instead, it details specific financial commitments related to executive compensation and severance:
- Severance Charge: The Company expects to record a charge of approximately $5 million for the quarter ended March 31, 2026, related to the departure of the former CFO.
- New CFO Compensation (Daniel Gabbay):
- Base Salary: $500,000 per year.
- Target Cash Incentive: $625,000 (guaranteed at target for 2026).
- Equity Incentives: Target value of $1,375,000 (performance and time-based).
- Make-Whole Award: One-time restricted stock valued at $2,750,000, vesting over four years.
- Relocation Benefits: $300,000.
Material Changes Versus Prior Period
The primary material change is the transition of the Chief Financial Officer role:
- Departure: Austen B. Helfrich departed as Executive Vice President and Chief Financial Officer effective January 12, 2026. The separation was mutual and not due to any disagreement with management or auditors.
- Appointment: Daniel Gabbay was appointed as Executive Vice President and Chief Financial Officer, effective January 12, 2026. Mr. Gabbay previously served as a Managing Director in the Real Estate Investment Banking Group at RBC Capital Markets.
Outlook, Risks, and Contingencies
Management Commentary and Risks:
- The filing confirms the departure was amicable, mitigating risks associated with internal conflict.
- Severance Contingency: The $5 million charge for the former CFO is contingent upon the execution and non-revocation of a release agreement.
- Change-in-Control Provisions: The new CFO's agreement includes enhanced severance (2.5x base salary and average bonus) and full equity vesting in the event of a change in control.
- Restrictive Covenants: The new CFO is subject to non-compete restrictions for one year following a termination upon a change in control or termination other than for cause.
Key Facts for Investor Verification
- Verify the impact of the $5 million severance charge on the Q1 2026 earnings report.
- Confirm the total equity grant value of $4.125 million ($1.375M target + $2.75M make-whole) for the new CFO and its dilution effect.
- Monitor the execution of the release agreement required to finalize the former CFO's severance package.
- Review the new CFO's background in healthcare REIT investment banking to assess strategic alignment.